European Academy of Dermatology and Venereology Congress

European Academy of Dermatology and Venereology Congress

Source:

Sigurgeirsson B, et al. ePoster. High efficacy, safety and tolerability of secukinumab injection with 2 mL auto-injector (300 mg) in adult patients with moderate to severe plaque psoriasis: 52-week results from MATURE, a randomised, placebo-controlled trial. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 29-Oct. 2, 2021 (virtual meeting).

Disclosures: Sigurgeirsson reports consulting for and serving on an advisory board and as a speaker for Novartis. Please see the poster for all other authors’ relevant financial disclosures.
September 30, 2021
1 min read
Save

Secukinumab 2 mL auto-injector safe, efficacious in treating plaque psoriasis

Source:

Sigurgeirsson B, et al. ePoster. High efficacy, safety and tolerability of secukinumab injection with 2 mL auto-injector (300 mg) in adult patients with moderate to severe plaque psoriasis: 52-week results from MATURE, a randomised, placebo-controlled trial. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 29-Oct. 2, 2021 (virtual meeting).

Disclosures: Sigurgeirsson reports consulting for and serving on an advisory board and as a speaker for Novartis. Please see the poster for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Secukinumab 300 mg administered with an auto-injector pen showed significant efficacy and tolerability compared with placebo, according to clinical trial results presented at the EADV Congress virtual meeting.

“Currently two injections of secukinumab are required to deliver the recommended dose of 300 mg,” Bárdur Sigurgeirsson, MD, PhD, professor of dermatology at the University of Iceland, said in a recorded presentation. “In order to improve patient convenience, the 2 mL auto-injector was developed that can deliver 30mg of secukinumab.”

The multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 MATURE trial evaluated both the safety and efficacy of the secukinumab auto-injector in 122 patients with moderate to severe plaque psoriasis.

Subjects were randomly assigned to receive secukinumab 300 mg or placebo in a 2 mL auto-injector or in two 1 mL prefilled syringes.

The two secukinumab treatment groups showed similar efficacy. Psoriasis Area and Severity Index 75 was reported in 95.1% of those treated with the 2 mL autoinjector and 83.2% of those who received two 1 mL doses, compared with 10% of those in the placebo group.

IGA of 0/1 was recorded in 75.6% and 68.1% of the treatment groups, respectively, compared with 7.6% of the placebo group.

Researchers also observed quality of life improvements in the secukinumab treatment groups. Dermatology Life Quality Index scores of 0/1 were reported in 71.1% and 72.5% of the respective treatment groups at week 12, compared with 8.1% of the placebo group.

Patients successfully self-administered the auto-injector 95.7% of the time.

“Secukinumab 300 mg administered with the 2 mL auto-injector demonstrated significantly superior efficacy over placebo, good tolerability and convenience of administration in patients with moderate to severe plaque psoriasis,” Sigurgeirsson said.